Amgen2021: Advanced Solid Tumors with KRAS p.G12C Mutation - Clinical Trial
What is the Purpose of this Study?
We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.
Colorectal Adenocarcinoma with KRAS p.G12C Mutation
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with advanced or metastatic colorectal adenocarcinoma with KRAS p.G12C mutation
- Have not received any previous therapy for metastatic disease
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
What is Involved?
If you choose to join this study, you will:
- Get a random assignment (like a coin flip) to 1 of 2 groups
-- One group will get the study drug combination of sotorasib, panitumumab, and FOLFIRI
-- The other group will get FOLFIRI either on its own or with another drug called bevacizumab-awwb
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)
Study Details
